The sad plight of cell therapy for heart failure: causes and consequences

Keywords

Cell therapy / heart failure / stem cells / progenitor cells / cardiac repair

References

[1] Bolli R,Tang XL.Cell therapy in patients with heart failure: a comprehensive review and emerging concepts.Cardiovasc Res2021:cvab135

[2] Bolli R. The plight of cell therapy for heart failure why research should continue. Curr Opin Cardiol Forthcoming 2022.

[3] Bolli R.Time to end the war on cell therapy.Eur J Heart Fail2020;22:893-7

[4] Beltrami AP,Torella D.Adult cardiac stem cells are multipotent and support myocardial regeneration.Cell2003;114:763-76

[5] Makkar RR,Cheng K.Intracoronary cardiosphere-derived cells for heart regeneration after myocardial infarction (CADUCEUS): a prospective, randomised phase 1 trial.Lancet2012;379:895-904 PMCID:PMC4326004

[6] Hong KU,Li QH.c-kit+ Cardiac stem cells alleviate post-myocardial infarction left ventricular dysfunction despite poor engraftment and negligible retention in the recipient heart.PLoS One2014;9:e96725 PMCID:PMC4013035

[7] Hong KU,Guo Y.A highly sensitive and accurate method to quantify absolute numbers of c-kit+ cardiac stem cells following transplantation in mice.Basic Res Cardiol2013;108:346 PMCID:PMC3684056

[8] Bolli R,Guo Y.After the storm: an objective appraisal of the efficacy of c-kit+ cardiac progenitor cells in preclinical models of heart disease.Can J Physiol Pharmacol2021;99:129-39 PMCID:PMC8299902

[9] Bolli R.Stem cells: Cell therapy for cardiac repair: what is needed to move forward?.Nat Rev Cardiol2017;14:257-8

[10] Sanganalmath SK.Cell therapy for heart failure: a comprehensive overview of experimental and clinical studies, current challenges, and future directions.Circ Res2013;113:810-34 PMCID:PMC3892665

[11] Keith MC.“String theory” of c-kit ^pos cardiac cells: a new paradigm regarding the nature of these cells that may reconcile apparently discrepant results.Circ Res2015;116:1216-30 PMCID:PMC4432841

[12] Wysoczynski M,Bolli R.New paradigms in cell therapy: repeated dosing, intravenous delivery, immunomodulatory actions, and new cell types.Circ Res2018;123:138-58 PMCID:PMC6050028

[13] Zhu K,Ni C.Lack of remuscularization following transplantation of human embryonic stem cell-derived cardiovascular progenitor cells in infarcted nonhuman primates.Circ Res2018;122:958-69

[14] Wysoczynski M.A realistic appraisal of the use of embryonic stem cell-based therapies for cardiac repair.Eur Heart J2020;41:2397-404 PMCID:PMC7327535

[15] Karantalis V.Use of mesenchymal stem cells for therapy of cardiac disease.Circ Res2015;116:1413-30 PMCID:PMC4429294

[16] Bolli R,Sanganalmath SK.Intracoronary delivery of autologous cardiac stem cells improves cardiac function in a porcine model of chronic ischemic cardiomyopathy.Circulation2013;128:122-31 PMCID:PMC3807652

[17] Tang XL,Sanganalmath SK.Effects of intracoronary infusion of escalating doses of cardiac stem cells in rats with acute myocardial infarction.Circ Heart Fail2015;8:757-65 PMCID:PMC4512882

[18] Tang XL,Rokosh G.Long-term outcome of administration of c-kit(POS) cardiac progenitor cells after acute myocardial infarction: transplanted cells do not become cardiomyocytes, but structural and functional improvement and proliferation of endogenous cells persist for at least one year.Circ Res2016;118:1091-105

[19] Tokita Y,Li Q.Repeated administrations of cardiac progenitor cells are markedly more effective than a single administration: a new paradigm in cell therapy.Circ Res2016;119:635-51 PMCID:PMC4992406

[20] Tang XL,Li Q.Repeated administrations of cardiac progenitor cells are superior to a single administration of an equivalent cumulative dose.J Am Heart Assoc2018;7:e007400 PMCID:PMC5850187

[21] Wysoczynski M,Moore JB 4th.Myocardial reparative properties of cardiac mesenchymal cells isolated on the basis of adherence.J Am Coll Cardiol2017;69:1824-38 PMCID:PMC5628504

[22] Guo Y,Nong Y.Repeated doses of cardiac mesenchymal cells are therapeutically superior to a single dose in mice with old myocardial infarction.Basic Res Cardiol2017;112:18 PMCID:PMC5655998

[23] Cai C,Teng L.Preconditioning human cardiac stem cells with an HO-1 inducer exerts beneficial effects after cell transplantation in the infarcted murine heart.Stem Cells2015;33:3596-607 PMCID:PMC4766973

[24] Li Q,Ou Q.Intracoronary administration of cardiac stem cells in mice: a new, improved technique for cell therapy in murine models.Basic Res Cardiol2011;106:849-64 PMCID:PMC3640450

[25] Guo Y,Li Q.Comparison of one and three intraventricular injections of cardiac progenitor cells in a murine model of chronic ischemic cardiomyopathy.Stem Cell Rev Rep2021;17:604-15 PMCID:PMC8043991

[26] Eschenhagen T,Braun T.Cardiomyocyte regeneration: a consensus statement.Circulation2017;136:680-6 PMCID:PMC5557671

[27] Vagnozzi RJ,Sargent MA.An acute immune response underlies the benefit of cardiac stem cell therapy.Nature2020;577:405-9 PMCID:PMC6962570

[28] Bolli R.Cell therapy for acute myocardial infarction: requiescat in Pace.Eur Heart J2020;41:3711-4

[29] Mathur A,Bartunek J.BAMI GroupThe effect of intracoronary infusion of bone marrow-derived mononuclear cells on all-cause mortality in acute myocardial infarction: the BAMI trial.Eur Heart J2020;41:3702-10 PMCID:PMC7666866

[30] Patel AN,Quyyumi AA.Ixmyelocel-T for patients with ischaemic heart failure: a prospective randomised double-blind trial.Lancet2016;387:2412-21

[31] Mathiasen AB,Jørgensen E.Bone marrow-derived mesenchymal stromal cell treatment in patients with ischaemic heart failure: final 4-year follow-up of the MSC-HF trial.Eur J Heart Fail2020;22:884-92

[32] Bolli R,Hare JM.Cardiovascular Cell Therapy Research Network (CCTRN)A Phase II study of autologous mesenchymal stromal cells and c-kit positive cardiac cells, alone or in combination, in patients with ischaemic heart failure: the CCTRN CONCERT-HF trial.Eur J Heart Fail2021;23:661-74 PMCID:PMC8357352

[33] Borow KM,Greenberg B.Phase 3 DREAM-HF trial of mesenchymal precursor cells in chronic heart failure.Circ Res2019;125:265-81 PMCID:PMC6688717

[34] Kosyakovsky L. Stem cells did not decrease heart failure readmissions in DREAM-HF. Available from: https://cardiologynownews.org/stem-cells-did-not-decrease-heart-failure-readmissions-in-dream-hf/ [Last accessed on 25 Feb]

[35] Heldman AW,Fishman JE.Transendocardial mesenchymal stem cells and mononuclear bone marrow cells for ischemic cardiomyopathy: the TAC-HFT randomized trial.JAMA2014;311:62-73 PMCID:PMC4111133

[36] Oransky I. Harvard and the Brigham recommend 31 retractions for cardiac stem cell work. Available from: https://retractionwatch.com/2018/10/14/harvard-and-the-brigham-recommend-31-retractions-for-cardiac-stem-cell-work/ [Last accessed on 25 Feb]

[37] Virani SS,Benjamin EJ.American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics SubcommitteeHeart disease and stroke statistics-2020 update: a report from the American heart association.Circulation2020;141:e139-596